Biogen starts dosing in Phase III trial of Friedreich ataxia therapy
Biogen has commenced dosing in the Phase III BRAVE study to assess omaveloxolone in children of two to less than …
Post
-
-
New study investigates autism spectrum disorder prevalence
Autism spectrum disorder (ASD) is a neurodevelopmental disorder that includes a variety of differences or challenges with social communication and …
-
MSD and Daiichi announce first subject dosing in prostate cancer trial
MSD and Daiichi Sankyo have announced first subject dosing in the randomised IDeate-Prostate01 Phase III trial of ifinatamab deruxtecan (I-DXd) …
-
NHS England chair suggests England can learn from European health schemes
With the 10-year Health Plan on the horizon, the NHS could learn some tricks from France, Germany and the Nordics. At …
-
Skyhawk begins dosing in Huntington’s disease trial of SKY-0515
Skyhawk Therapeutics has dosed the first subject in the randomised Phase II/III FALCON-HD trial of the oral small-molecule RNA splicing …
-
FDA Commissioner envisions fewer delays, more clinical trial flexibility and AI use
US Food and Drug Administration (FDA) Commissioner Dr. Marty Makary addressed concerns about the recent cuts impacting the agency’s ability …
-
Ensuring success in oncology clinical trials
Oncology clinical trials are complex and costly, making a successful setup critical. Facing challenges such as long timelines and patient …
-
Lyell reports new clinical data from trial of large B-cell lymphoma therapy
Lyell Immunopharma has reported new clinical data from the Phase I/II clinical trial of autologous dual-targeting CD19/CD20 chimeric antigen receptor …
-
Ventyx reports positive outcomes from trial of VTX3232 for Parkinson’s
Ventyx Biosciences has reported encouraging top-line outcomes from its single-centre Phase IIa trial of the central nervous system (CNS)-penetrant NLRP3 …
-
Genomics to roll out predictive clinical test across UK
Oxford-based company Genomics is launching its Health Insights test across the UK, which will be used to predict and prevent …
-
AI-powered orchestration: Bringing the benefits to personalized therapy
Cell and gene therapies represent a groundbreaking advancement in medical science, offering transformative opportunities for treating complex and previously untreatable …
-
Clarametyx to advance trial of CMTX-101 with DMC approval
Clarametyx Biosciences has received approval from the Independent Data Monitoring Committee (DMC) to progress its Phase Ib/IIa trial of CMTX-101, an …
-
FDA clears Ocugen’s IND amendment for trial of Stargardt disease treatment
The US Food and Drug Administration (FDA) has approved Ocugen’s investigational new drug (IND) amendment to initiate a Phase II/III …
-
EHA 2025: Anito-cel to disrupt CAR-T market in multiple myeloma
At the 2025 European Hematology Association (EHA) Congress, held from June 12 to June 15 in Milan, Italy, updated results …
-
Childhood traumatic events associated with endometriosis risk
According to the World Health Organization, endometriosis affects approximately one in ten women and girls of reproductive age globally. There …
